α-Synuclein in Parkinson’s disease: causal or bystander?

Journal article
(Review article)


Publication Details

Author(s): Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Krüger R, Müller T, Reichmann H, Rieß O, Storch A, Strobel S, van Eimeren T, Völker HU, Winkler J, Winklhofer KF, Wüllner U, Zunke F, Monoranu CM
Journal: Journal of Neural Transmission
Publication year: 2019
ISSN: 0300-9564
eISSN: 1435-1463


Abstract

Parkinson’s disease (PD) comprises a spectrum of disorders with differing subtypes, the vast majority of which share Lewy bodies (LB) as a characteristic pathological hallmark. The process(es) underlying LB generation and its causal trigger molecules are not yet fully understood. α-Synuclein (α-syn) is a major component of LB and SNCA gene missense mutations or duplications/triplications are causal for rare hereditary forms of PD. As typical sporadic PD is associated with LB pathology, a factor of major importance is the study of the α-syn protein and its pathology. α-Syn pathology is, however, also evident in multiple system atrophy (MSA) and Lewy body disease (LBD), making it non-specific for PD. In addition, there is an overlap of these α-synucleinopathies with other protein-misfolding diseases. It has been proven that α-syn, phosphorylated tau protein (pτ), amyloid beta (Aβ) and other proteins show synergistic effects in the underlying pathogenic mechanisms. Multiple cell death mechanisms can induce pathological protein-cascades, but this can also be a reverse process. This holds true for the early phases of the disease process and especially for the progression of PD. In conclusion, while rare SNCA gene mutations are causal for a minority of familial PD patients, in sporadic PD (where common SNCA polymorphisms are the most consistent genetic risk factor across populations worldwide, accounting for 95% of PD patients) α-syn pathology is an important feature. Conversely, with regard to the etiopathogenesis of α-synucleinopathies PD, MSA and LBD, α-syn is rather a bystander contributing to multiple neurodegenerative processes, which overlap in their composition and individual strength. Therapeutic developments aiming to impact on α-syn pathology should take this fact into consideration.


FAU Authors / FAU Editors

Winkler, Jürgen Prof. Dr.
Molekular-Neurologische Abteilung in der Neurologischen Klinik


External institutions with authors

Christian-Albrechts-Universität zu Kiel
Eberhard Karls Universität Tübingen
Johannes Gutenberg-Universität Mainz
Julius-Maximilians-Universität Würzburg
Leopoldina Krankenhaus Schweinfurt
Parkinson-Klinik Ortenau
Rheinische Friedrich-Wilhelms-Universität Bonn
Ruhr-Universität Bochum (RUB)
Technische Universität Dresden
Universität Rostock
Universitätsklinikum Köln
Universitätsklinikum Leipzig
Universitätsklinikum Würzburg
University of Luxembourg


How to cite

APA:
Riederer, P., Berg, D., Casadei, N., Cheng, F., Classen, J., Dresel, C.,... Monoranu, C.M. (2019). α-Synuclein in Parkinson’s disease: causal or bystander? Journal of Neural Transmission. https://dx.doi.org/10.1007/s00702-019-02025-9

MLA:
Riederer, Peter, et al. "α-Synuclein in Parkinson’s disease: causal or bystander?" Journal of Neural Transmission (2019).

BibTeX: 

Last updated on 2019-12-07 at 13:08